Two digital health companies have gone public this year: Hinge Health and Omada Health. During a recent panel discussion, venture capitalists shared lessons learned about health tech in the public markets.
In Venrock’s annual survey of healthcare leaders, respondents expected most digital health startups that went public during the pandemic to see their valuations fall by the end of the year.
In a recent interview, Esperion president and CEO, Sheldon Koenig talks about the reality of statin intolerance and his company’s expansion into new diseases
The San Francisco-based startup is one of several that have been raising money over the past couple of weeks in areas like neurology, oncology and women's health.
Although the majority of respondents believe the creation of new healthcare IT companies will increase significantly or somewhat over the next two years, they still have concerns regarding talent/hiring and funding.
The appointment of Grand Rounds Chief Medical Officer Ami Parekh fits with the company's broadened mission and ambitions to become a health navigator for the employer market.
The Medicare Advantage startup pitches itself as a "payvidor" as it goes against a host of competitors including Bright Health, Clover Health and Oscar Health.
Greenway Health blends smart technology with human expertise to elevate revenue cycle.
The oversubscribed round comes just four months after acquisition of GSK's gene therapy portfolio.
A Venrock survey of 300 healthcare industry insiders spanning health IT vendors, investors, healthcare providers and professional service folks offered a window into their thoughts on investment regrets and sources of concern for digital health.
Top Silicon Valley venture capitalists advocate for machine learning, deep learning and AI to be used in non-clinical applications where you wouldn't have to worry about FDA and the potential to harm a patient.
"We now need to do more work on creating local market competition and price pressure," said Venrock Partner Bob Kocher in a Q&A.
In a landscape where complexity has long been the norm, the power of one lies not just in unification, but in intelligence and automation.
Who will be the winners and losers of health IT consolidation as M&A activity ramps up and the appetite for IPOs cools?
Virta Health's approach is designed to help patients lower their hemoglobin A1c levels and reduce or eliminate prescription medications. The goal is to reverse the effects of Type 2 diabetes, and cure it.
Venrock has closed its eighth fund, raising $450 million for future technology and healthcare investments. According to Venrock Partner Bryan Roberts, it's a size that will optimize performance; "not too big and not too small, but just about right."
"I'm a skeptic of public market valuations, but a true believer in biotechnology," said Hans Hinrichs, managing director of Silicon Valley Bank's Life Sciences and Healthcare Group. "We're probably sitting on the biggest opportunity in the history of investment."
Also, AstraZeneca has agreed to acquire ZS Pharma in a $2.7 billion deal.